Cognition Therapeutics rises on positive results from mid-stage Alzheimer's study

Cognition Therapeutics

22/08/2024 15:48

** Shares of drug developer Cognition Therapeutics  CGTX.O 
rise 3.7% to 77 cents 
    ** Co reports positive results from mid-stage study testing
its experimental drug to treat Alzheimer's disease 
    ** Co says patients treated with CT1812 showed signs of
improvement in the symptoms of the disease 
    ** The drug shows improvement in global and relative theta
power in the brain - that are associated with cognitive decline
in people with Alzheimer's disease
    ** CT1812 was observed to be well tolerated with mild or
moderate treatment related adverse events occurring in 11
patients in the CT1812-treated arm and 6 on placebo
    ** The study enrolled 16 adults with mild-to-moderate
Alzheimer's disease 
    ** Including session moves, stock down 57.9% YTD 

 (Reporting by Sneha S K)
 ((Sneha.SK@thomsonreuters.com;))